申请人:KANDULA Mahesh
公开号:US20150141500A1
公开(公告)日:2015-05-21
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder, migraine prophylaxis, eating disorders, bipolar disorder, post-herpetic neuralgia, insomnia, ankylosing spondylitis, recurring biliary dyskinesia, nocturnal enuresis, cyclic vomiting syndrome, post-traumatic stress disorder (PTSD) and neuropathy.
该发明涉及公式I或其药用可接受盐的化合物,以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I化合物的有效量的药物组合物,以及用于治疗神经系统疾病的方法,可制备成口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂形式。这些组合物可用于治疗抑郁症、焦虑症、注意力缺陷多动障碍、偏头痛预防、进食障碍、躁郁症、带状疱疹后神经痛、失眠、强直性脊柱炎、复发性胆道运动障碍、夜尿症、周期性呕吐综合征、创伤后应激障碍(PTSD)和神经病。